Value Added Technology Co., Ltd. (KOSDAQ:043150)
 21,950
 -350 (-1.57%)
  Oct 31, 2025, 3:30 PM KST
Value Added Technology Revenue
Value Added Technology had revenue of 110.62B KRW in the quarter ending June 30, 2025, with 8.47% growth. This brings the company's revenue in the last twelve months to 400.92B, up 3.26% year-over-year. In the year 2024, Value Added Technology had annual revenue of 385.19B with 0.06% growth.
Revenue (ttm) 
 400.92B
Revenue Growth 
 +3.26%
P/S Ratio 
 0.83
Revenue / Employee 
 1.31B
Employees 
 307
Market Cap 
331.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 385.19B | 249.51M | 0.06% | 
| Dec 31, 2023 | 384.95B | -10.11B | -2.56% | 
| Dec 31, 2022 | 395.06B | 56.08B | 16.54% | 
| Dec 31, 2021 | 338.98B | 94.67B | 38.75% | 
| Dec 31, 2020 | 244.31B | -27.39B | -10.08% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |